EU

STADA Approves €20 Million Expansion at Hemofarm Facility

German pharmaceutical group STADA has approved a €20 million investment to expand production at Hemofarm’s manufacturing complex, strengthening the Serbian facility’s position within the group’s international production network. STADA CEO said the group’s global executive board approved the investment. The project will expand production and add manufacturing capacity at the Vršac site. Hemofarm already supplies pharmaceutical products from Vršac to markets across the European Union, the Middle East and other international destinations. Germany is the company’s largest export market. Hemofarm’s…